GlassScriptPhysician profile
Christopher Lee Colglazier
NPI 1679555486
$22,392.11
in general payments reported to CMS, 2019-2025
44 companies · $2,289 in 2025
The $2,289 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,160 · 2020: $2,095 · 2021: $2,431 · 2022: $2,917 · 2023: $2,413 · 2024: $3,089 · 2025: $2,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,636 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,636.46 |
| Education | $153.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,539.39 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Lilly USA, LLC | $3,806.14 | 2019-2025 | Taltz |
| Janssen Biotech, INC. | $2,851.20 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $2,643.08 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $1,973.42 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,148.15 | 2019-2025 | |
| Pfizer INC. | $819.50 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $683.28 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $562.14 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $531.45 | 2019-2023 | |
| Glaxosmithkline, LLC. | $338.04 | 2019-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $321.17 | 2022-2025 | Lupkynis |
| Genentech USA, INC. | $289.02 | 2019-2025 | Actemra, Gazyva |
| Mallinckrodt Hospital Products INC. | $186.68 | 2020-2022 | |
| Radius Health, INC. | $174.32 | 2020-2025 | Tymlos |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Colglazier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.